RCM
DAWN

Regency Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Regency Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,000
Closed -$138K – 48
2024
Q2 		$138K Sell
10,000
-1,000
-9% -$14.6K 0.09% 46
2024
Q1 		$182K Sell
11,000
-1,000
-8% -$15K 0.12% 48
2023
Q4 		$175K Hold
12,000
– – 0.12% 51
2023
Q3 		$147K Hold
12,000
– – 0.13% 42
2023
Q2 		$143K Buy
+12,000
New +$157K 0.12% 42

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Regency Capital Management's DAWN Position: Q3 2024 in Review

Regency Capital Management sold out of Day One Biopharmaceuticals (DAWN) in Q3 2024, closing a stake of 10,000 shares — an estimated $138K sold.

Regency Capital Management first reported a position in DAWN in Q2 2023 and held it in 5 quarters. The position peaked at $182K in Q1 2024. 166 funds tracked by Wall St. Rank hold DAWN as of Q3 2024.

  • Regency Capital Management reported no remaining Day One Biopharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Regency Capital Management sold 10,000 Day One Biopharmaceuticals shares in Q3 2024, an estimated $138K.
  • Regency Capital Management first reported a position in Day One Biopharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Regency Capital Management's Day One Biopharmaceuticals position peaked at $182K in Q1 2024.
  • 166 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q3 2024.

Based on Regency Capital Management's 13F filing for Q3 2024, filed 4 Oct 2024.